Melinta Therapeutics Demonstrates Potency of Delafloxacin against Bacteria Associated with Respiratory Tract Infections

Melinta Therapeutics, a privately held company developing novel antibiotics to treat bacterial infections, announced in vitro results demonstrating delafloxacin’s activity against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, three bacteria commonly associated with respiratory tract infections. Delafloxacin is an investigational fluoroquinolone in late-stage development for the treatment of acute bacterial skin and skin structure infections (ABSSSI). In clinical trials, delafloxacin is being tested in both IV and oral formulations. Delafloxacin has been studied in over 2,000 subjects to date in 27 clinical studies.